JWH-184
Overview[edit]

JWH-184 is a synthetic cannabinoid that acts as a potent agonist at the cannabinoid receptors. It is part of the naphthoylindole family of compounds, which are known for their ability to mimic the effects of tetrahydrocannabinol (THC), the primary psychoactive component of cannabis.
Chemical Properties[edit]
JWH-184 has the chemical formula C24H23NO and a molecular weight of 341.45 g/mol. It is characterized by its naphthoylindole structure, which consists of a naphthalene ring linked to an indole moiety. This structure is crucial for its activity at cannabinoid receptors.
Pharmacology[edit]
JWH-184 functions as a full agonist at both the CB1 and CB2 cannabinoid receptors. These receptors are part of the endocannabinoid system, which plays a role in regulating various physiological processes such as pain, mood, and appetite. The activation of these receptors by JWH-184 can lead to effects similar to those produced by natural cannabinoids.
Legal Status[edit]
Due to its potential for abuse and lack of medical use, JWH-184, like many synthetic cannabinoids, is classified as a controlled substance in many jurisdictions. The legal status of JWH-184 can vary significantly between countries and regions.
Synthesis[edit]
The synthesis of JWH-184 involves the condensation of a naphthoyl chloride with an indole derivative. This reaction typically requires the use of a base to facilitate the formation of the naphthoylindole structure. The synthesis of JWH-184 is similar to that of other compounds in the JWH series, named after the chemist John W. Huffman, who first synthesized many of these compounds.
Potential Risks and Effects[edit]

The use of JWH-184, like other synthetic cannabinoids, can pose significant health risks. These compounds can produce unpredictable and sometimes severe effects, including tachycardia, hypertension, hallucinations, and psychosis. The lack of regulation and quality control in the production of synthetic cannabinoids further increases the risk of adverse effects.
Related Pages[edit]
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

Tired of being overweight?
Special offer:
Budget GLP-1 weight loss medications
- Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
- Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay
✔ Same-week appointments, evenings & weekends
Learn more:
- GLP-1 weight loss clinic NYC
- W8MD's NYC medical weight loss
- W8MD Philadelphia GLP-1 shots
- Philadelphia GLP-1 injections
- Affordable GLP-1 shots NYC
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian